After subtracting ER+/PR+ and erbB2+ breast tumors, there remains a miscellaneous collection of so-called “triple negative” tumors (15–20% of total tumors) that are ill defined with respect to their molecular and cellular basis. Here, ERBB2 is linked to breast neoplasm.